Postchemotherapy residual masses in germ cell tumor patients: Our experience

F. Morelli, L. Tozzi, P. Setola, M. Bisceglia, V. Ricci Barbini, E. Maiello

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: The nature of post-chemotherapy tumor residuals can be determined only by excision and histological examination, but at present no consensus has been reached as to whether all patients with residual masses should undergo adjunctive surgery. Patients and methods: Between August 1991 and September 2004, 120 patients with metastatic germ cell tumors were diagnosed at our hospital and 35 of these patients (30%) underwent adjunctive surgery after cisplatin-based chemotherapy. If serum tumor markers were still raised salvage chemotherapy was administered. Results: At the time of surgical intervention 30 patients (86%) had a partial remission with normal markers. Necrosis, differentiated teratoma and undifferentiated tumor were found in nine (30%), 19 (63%) and two (7%) of all patients. Five patients (14%) underwent postchemotherapy resections after second-line cisplatin-based combination chemotherapy. Four of the 35 patients died as a result of their malignant germ cell tumor. The median observation time after the initial diagnosis was 99 months (range 15-172 months). Conclusions: Secondary resection of residual masses after first or second-line chemotherapy is still an essential part of the treatment of metastatic testicular cancer. Resection of mature teratoma or viable cancer adds to long-term event-free and overall survival in these patients.

Original languageEnglish
JournalAnnals of Oncology
Volume17
Issue numberSUPPL. 7
DOIs
Publication statusPublished - Jun 2006

Fingerprint

Germ Cell and Embryonal Neoplasms
Drug Therapy
Teratoma
Cisplatin
Testicular Neoplasms
Residual Neoplasm
Tumor Biomarkers
Combination Drug Therapy
Disease-Free Survival
Neoplasms
Necrosis
Biomarkers
Observation

Keywords

  • Chemotherapy
  • Germ cell tumors
  • Lymphadenectomy
  • Necrosis
  • Post chemotherapy residual
  • Teratoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Postchemotherapy residual masses in germ cell tumor patients : Our experience. / Morelli, F.; Tozzi, L.; Setola, P.; Bisceglia, M.; Barbini, V. Ricci; Maiello, E.

In: Annals of Oncology, Vol. 17, No. SUPPL. 7, 06.2006.

Research output: Contribution to journalArticle

Morelli, F. ; Tozzi, L. ; Setola, P. ; Bisceglia, M. ; Barbini, V. Ricci ; Maiello, E. / Postchemotherapy residual masses in germ cell tumor patients : Our experience. In: Annals of Oncology. 2006 ; Vol. 17, No. SUPPL. 7.
@article{e87013514b544e059dd7e8748e75d931,
title = "Postchemotherapy residual masses in germ cell tumor patients: Our experience",
abstract = "Background: The nature of post-chemotherapy tumor residuals can be determined only by excision and histological examination, but at present no consensus has been reached as to whether all patients with residual masses should undergo adjunctive surgery. Patients and methods: Between August 1991 and September 2004, 120 patients with metastatic germ cell tumors were diagnosed at our hospital and 35 of these patients (30{\%}) underwent adjunctive surgery after cisplatin-based chemotherapy. If serum tumor markers were still raised salvage chemotherapy was administered. Results: At the time of surgical intervention 30 patients (86{\%}) had a partial remission with normal markers. Necrosis, differentiated teratoma and undifferentiated tumor were found in nine (30{\%}), 19 (63{\%}) and two (7{\%}) of all patients. Five patients (14{\%}) underwent postchemotherapy resections after second-line cisplatin-based combination chemotherapy. Four of the 35 patients died as a result of their malignant germ cell tumor. The median observation time after the initial diagnosis was 99 months (range 15-172 months). Conclusions: Secondary resection of residual masses after first or second-line chemotherapy is still an essential part of the treatment of metastatic testicular cancer. Resection of mature teratoma or viable cancer adds to long-term event-free and overall survival in these patients.",
keywords = "Chemotherapy, Germ cell tumors, Lymphadenectomy, Necrosis, Post chemotherapy residual, Teratoma",
author = "F. Morelli and L. Tozzi and P. Setola and M. Bisceglia and Barbini, {V. Ricci} and E. Maiello",
year = "2006",
month = "6",
doi = "10.1093/annonc/mdl966",
language = "English",
volume = "17",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "SUPPL. 7",

}

TY - JOUR

T1 - Postchemotherapy residual masses in germ cell tumor patients

T2 - Our experience

AU - Morelli, F.

AU - Tozzi, L.

AU - Setola, P.

AU - Bisceglia, M.

AU - Barbini, V. Ricci

AU - Maiello, E.

PY - 2006/6

Y1 - 2006/6

N2 - Background: The nature of post-chemotherapy tumor residuals can be determined only by excision and histological examination, but at present no consensus has been reached as to whether all patients with residual masses should undergo adjunctive surgery. Patients and methods: Between August 1991 and September 2004, 120 patients with metastatic germ cell tumors were diagnosed at our hospital and 35 of these patients (30%) underwent adjunctive surgery after cisplatin-based chemotherapy. If serum tumor markers were still raised salvage chemotherapy was administered. Results: At the time of surgical intervention 30 patients (86%) had a partial remission with normal markers. Necrosis, differentiated teratoma and undifferentiated tumor were found in nine (30%), 19 (63%) and two (7%) of all patients. Five patients (14%) underwent postchemotherapy resections after second-line cisplatin-based combination chemotherapy. Four of the 35 patients died as a result of their malignant germ cell tumor. The median observation time after the initial diagnosis was 99 months (range 15-172 months). Conclusions: Secondary resection of residual masses after first or second-line chemotherapy is still an essential part of the treatment of metastatic testicular cancer. Resection of mature teratoma or viable cancer adds to long-term event-free and overall survival in these patients.

AB - Background: The nature of post-chemotherapy tumor residuals can be determined only by excision and histological examination, but at present no consensus has been reached as to whether all patients with residual masses should undergo adjunctive surgery. Patients and methods: Between August 1991 and September 2004, 120 patients with metastatic germ cell tumors were diagnosed at our hospital and 35 of these patients (30%) underwent adjunctive surgery after cisplatin-based chemotherapy. If serum tumor markers were still raised salvage chemotherapy was administered. Results: At the time of surgical intervention 30 patients (86%) had a partial remission with normal markers. Necrosis, differentiated teratoma and undifferentiated tumor were found in nine (30%), 19 (63%) and two (7%) of all patients. Five patients (14%) underwent postchemotherapy resections after second-line cisplatin-based combination chemotherapy. Four of the 35 patients died as a result of their malignant germ cell tumor. The median observation time after the initial diagnosis was 99 months (range 15-172 months). Conclusions: Secondary resection of residual masses after first or second-line chemotherapy is still an essential part of the treatment of metastatic testicular cancer. Resection of mature teratoma or viable cancer adds to long-term event-free and overall survival in these patients.

KW - Chemotherapy

KW - Germ cell tumors

KW - Lymphadenectomy

KW - Necrosis

KW - Post chemotherapy residual

KW - Teratoma

UR - http://www.scopus.com/inward/record.url?scp=33745628090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745628090&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdl966

DO - 10.1093/annonc/mdl966

M3 - Article

C2 - 16760276

AN - SCOPUS:33745628090

VL - 17

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 7

ER -